Блог – PharmCAT.NET

PharmCAT.NET

Биостатистика, фармакокинетика и клинические исследования.

Домашняя страница
- О сайте
Материалы
- Быстрые команды R Project
- Ссылки
Инструменты
- Рандомизационный список
Блог
Контакты
Профиль

Найти:

Свежие записи

Long WS Wide: или про то, как выполнить анализ разницы изменений между группами
Частые вопросы: Регистрация и экспертиза по правилам ЕАЭС
Главные ошибки при формировании базы данных в MS Excel
Тест ClinicalTrialUtilities и ReplicateBE на Raspberry Pi 4
Julia:ReplicateBE – release 0.2.0

Галерея

Human medicines European public assessment report (EPAR): Kisplyx, lenvatinib, Carcinoma, Renal Cell, Date of authorisation: 25/08/2016, Revision: 18, Status: Authorised
Source: EMA - Human medicines: European public assessment reports (EPARs) Published on 2023-03-31
Identification of Medicinal Products — Implementation and Use
Source: FDA - What's New: Drugs RSS Feed Published on 2023-03-31 By FDA
Newly Added Guidance Documents
Source: FDA - What's New: Drugs RSS Feed Published on 2023-03-31 By FDA
Human medicines European public assessment report (EPAR): Lydisilka, estetrol,drospirenone, Contraceptives, Oral, Date of authorisation: 19/05/2021, Revision: 3, Status: Authorised
Source: EMA - Human medicines: European public assessment reports (EPARs) Published on 2023-03-31
Human medicines European public assessment report (EPAR): Grasustek, pegfilgrastim, Neutropenia, Date of authorisation: 20/06/2019, Revision: 4, Status: Authorised
Source: EMA - Human medicines: European public assessment reports (EPARs) Published on 2023-03-31
Summary of opinion: Pedmarqsi,sodium thiosulfate, 30/03/2023, Positive
Source: EMA - New medicines: human Published on 2023-03-31
Summary of opinion: Omvoh,mirikizumab, 30/03/2023, Positive
Source: EMA - New medicines: human Published on 2023-03-31
Procter & Gamble Manufactura S. de R.L. de C.V. - 650837 - 03/27/2023
Source: FDA - What's New: Drugs RSS Feed Published on 2023-03-31 By FDA
Procter & Gamble Manufactura S. de R.L. de C.V. - 650837 - 03/14/2023
Source: FDA - What's New: Drugs RSS Feed Published on 2023-03-31 By FDA
Summary of opinion: Tenkasi (previously Orbactiv),oritavancin, 30/03/2023, Positive
Source: EMA - New medicines: human Published on 2023-03-31
Summary of opinion: Ultomiris,ravulizumab, 30/03/2023, Positive
Source: EMA - New medicines: human Published on 2023-03-31
Summary of opinion: Ultomiris,ravulizumab, 30/03/2023, Positive
Source: EMA - New medicines: human Published on 2023-03-31
Summary of opinion: Neparvis,sacubitril,valsartan, 30/03/2023, Positive
Source: EMA - New medicines: human Published on 2023-03-31
Summary of opinion: Entresto,sacubitril,valsartan, 30/03/2023, Positive
Source: EMA - New medicines: human Published on 2023-03-31
Summary of opinion: Sugammadex Adroiq,sugammadex, 30/03/2023, Positive
Source: EMA - New medicines: human Published on 2023-03-31

Предыдущие записи

Тема: Scaffold от Danny Cooper.